To maximise the power in this study, we utilised young-onset cases (diagnosed at ≤60 yr) and control samples screened for either no PCa FH or low prostate-specific antigen (PSA; <0.5 ng/ml). The gene discussed is KLK3; the disease is posterior cortical atrophy.